Oragenics awarded additional $500,000 to further development of MU 1140, DPOLT antibiotics platform

Oragenics, Inc. (OTCBB:ORNI) (www.oragenics.com), a biopharmaceutical company, announced today that the National Science Foundation ("NSF") has awarded the Company an additional $500,000 in funds to support the previously awarded SBIR Phase II grant for the Company's DPOLT Lantibiotic Synthesis Platform.

David Hirsch, the Company's CEO said, "We are extremely pleased that the NSF has awarded the Company an additional $500,000 to further the development of MU 1140 and our DPOLT antibiotics platform. Each year, in the US alone, nearly two million people become infected with Healthcare-Associated Infections, or HAI's. The number of people that succumb to these infections is staggering. This problem has been exacerbated with the emergence of many multi-drug resistant strains of bacteria such as MRSA, VRE and Clostridium. This matching grant by the NSF will help to accelerate the development of our antibiotics program, and hopefully lead to more effective treatment for many of these life threatening infections."